Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
HUTCHMED clinical trials
Also known as Chi-Med.
The registry lists 118 studies whose lead sponsor is HUTCHMED or one of 1 company grouped under it. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Keep track of what changes. Save the HUTCHMED studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to HUTCHMED.
- Hutchison Medipharma Limited68 studies →Subsidiary
Something wrong?
- Hutchmed50 studiesSame company
Something wrong?
Related but not counted here: Shanghai Hutchison Pharmaceuticals Limited (affiliate).
Focus areas
Conditions HUTCHMED leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 118. Browse all 118 →
- HMPL-A830 in Solid TumorsRecruitingNCT07718581Phase 1/2
Sponsor listed in the registry: Hutchmed
- A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid TumorsRecruitingNCT07228247Phase 1/2
Sponsor listed in the registry: Hutchmed
- HMPL-A580 in Participants With Advanced or Metastatic Solid TumorRecruitingNCT07396584Phase 1/2
Sponsor listed in the registry: Hutchmed
- A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerRecruitingNCT06361888Phase 2/3
Sponsor listed in the registry: Hutchmed
- A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRecruitingNCT07409428Phase 3
Sponsor listed in the registry: Hutchmed
- HMPL-453 Tartrate in Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04353375Phase 2/3
Sponsor listed in the registry: Hutchmed
- A Clinical Study of HMPL-506 in Patients With Hematological MalignanciesRecruitingNCT06387082Phase 1
Sponsor listed in the registry: Hutchmed
- A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaRecruitingNCT06387069Phase 3
Sponsor listed in the registry: Hutchmed
- Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 MutationsRecruitingNCT07025018Phase 1
Sponsor listed in the registry: Hutchmed
- Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial CancerRecruitingNCT06584032Phase 3
Sponsor listed in the registry: Hutchmed
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaRecruitingNCT05015621Phase 3
Sponsor listed in the registry: Hutchison Medipharma Limited
- A Study of HMPL-415S1 in Patients With Advanced Malignant Solid TumorsRecruitingNCT05886374Phase 1
Sponsor listed in the registry: Hutchmed
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedNCT05522231Phase 2/3
Sponsor listed in the registry: Hutchmed
- Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLCompletedNCT06601504Phase 2
Sponsor listed in the registry: Hutchmed
- Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05009836Phase 3
Sponsor listed in the registry: Hutchmed
- A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 CapsulesCompletedNCT07643272Phase 1
Sponsor listed in the registry: Hutchmed
- The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate TabletsCompletedNCT07697157Phase 1
Sponsor listed in the registry: Hutchmed
- Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsCompletedNCT07644442Phase 1
Sponsor listed in the registry: Hutchmed
- Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedNCT05015608Phase 3
Sponsor listed in the registry: Hutchison Medipharma Limited
- HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaActive, not recruitingNCT05535933Phase 2/3
Sponsor listed in the registry: Hutchmed
- A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid TumorsCompletedNCT05173142Phase 1/2
Sponsor listed in the registry: Hutchison Medipharma Limited
- Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsCompletedNCT04923932Phase 2
Sponsor listed in the registry: Hutchison Medipharma Limited
- Phase III Study on HMPL-523 for Treatment of ITPCompletedNCT05029635Phase 3
Sponsor listed in the registry: Hutchmed
- A Study of HMPL-306 in Advanced Solid Tumors With IDH MutationsTerminatedNCT04762602Phase 1
Sponsor listed in the registry: Hutchmed
- An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaTerminatedNCT03779113Phase 1
Sponsor listed in the registry: Hutchmed
- Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate TabletsCompletedNCT07348133Phase 1
Sponsor listed in the registry: Hutchmed
- Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in HumansCompletedNCT07331194Phase 1
Sponsor listed in the registry: Hutchmed
- A Study of HMPL-306 in Advanced Hematological Malignancies With mIDHTerminatedNCT04764474Phase 1
Sponsor listed in the registry: Hutchmed
- A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)CompletedNCT03223376Phase 3
Sponsor listed in the registry: Hutchison Medipharma Limited
- Open-label Study of Surufatinib in Japanese PatientsCompletedNCT05077384Phase 1/2
Sponsor listed in the registry: Hutchmed
- The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)WithdrawnNCT06291415Phase 1
Sponsor listed in the registry: Hutchmed
- Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerCompletedNCT05509699Phase 2
Sponsor listed in the registry: Hutchison Medipharma Limited
- Study on Mass Balance of [14C]HMPL-306(Isocitrate Dehydrogenase Inhibitor) in Healthy Chinese Adult Male SubjectsCompletedNCT06671873Phase 1
Sponsor listed in the registry: Hutchmed
- Open-Label Surufatinib in European Patients With NETTerminatedNCT04579679Phase 2
Sponsor listed in the registry: Hutchmed
- A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT04577963Phase 1/2
Sponsor listed in the registry: Hutchmed
- Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With LymphomasTerminatedNCT03786926Phase 1
Sponsor listed in the registry: Hutchmed
- A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant NeoplasmCompletedNCT05429008Phase 1
Sponsor listed in the registry: Hutchmed
- Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsTerminatedNCT04579757Phase 1/2
Sponsor listed in the registry: Hutchmed
- HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT05190068Phase 1
Sponsor listed in the registry: Hutchmed
- Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedNCT04849351Phase 2
Sponsor listed in the registry: Hutchison Medipharma Limited
- : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid TumorsCompletedNCT03903705Phase 1/2
Sponsor listed in the registry: Hutchmed
- A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal CancerCompletedNCT04322539Phase 3
Sponsor listed in the registry: Hutchison Medipharma Limited
- Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT04923945Phase 3
Sponsor listed in the registry: Hutchison Medipharma Limited
- Tazemetostat for the Treatment of Relapsed/Refractory Follicular LymphomaCompletedNCT05467943Phase 2
Sponsor listed in the registry: Hutchmed
- A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory LymphomaCompletedNCT05713110Phase 2
Sponsor listed in the registry: Hutchmed
- A Study of HMPL-295S1 in Patients With Advanced Malignant Solid TumorsCompletedNCT04908046Phase 1
Sponsor listed in the registry: Hutchmed
- A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersCompletedNCT03251378Phase 1
Sponsor listed in the registry: Hutchison Medipharma Limited
- Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese SubjectsCompletedNCT05781906Phase 1
Sponsor listed in the registry: Hutchmed
- The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia PatientsCompletedNCT03951623Phase 1
Sponsor listed in the registry: Hutchison Medipharma Limited
- A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell NeoplasmsCompletedNCT02857998Phase 1
Sponsor listed in the registry: Hutchison Medipharma Limited